BioFactura Announces MTA with Rani Therapeutics

Published on :

BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Published on :

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021

USP launches an Office of Organizational Culture, Equity and Inclusion Excellence headed by Chief Equity Officer and Senior Advisor Debra Joy Pérez, Ph.D.

Published on :

The U.S. Pharmacopeia (USP) announces the launch of a new department, the Office of Organizational Culture, Equity and Inclusive Excellence (Equity Office). Headed by Chief Equity Officer (CEqO) and Senior Advisor to the CEO, Debra Joy Pérez, Ph.D. (she/her/ella), the Equity Office will shape and implement all diversity, equity, inclusion and belonging (DEIB) programs and initiatives.

AbbVie and Rockville’s REGENXBIO Announce Eye Care Collaboration

Published on :

AbbVie and REGENXBIO form a strategic partnership combining eye care and gene therapy expertise. Companies will develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases. REGENXBIO to receive $370 million upfront payment

Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease

Published on :

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced topline data from the Company’s study, conducted at the University of Maryland School of Medicine (UMSOM). The study, evaluating two lead Structurally Targeted Allosteric Regulators (STARs) compounds – GT-02287 and GT-02329 – for the treatment of Gaucher and GBA1 Parkinson’s Disease, demonstrated positive effects on all tested phenotypes.

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

Published on :

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 study to evaluate the safety and immunogenicity of a combination vaccine using Novavax’ seasonal influenza and COVID-19 vaccines. The clinical trial combines Novavax’ recombinant protein-based NVX-CoV2373 and NanoFlu™ vaccine candidates and patented saponin-based Matrix-M™ adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine). Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 clinical trials.

Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago | Business Wire

Published on :

Data Center Firm DataBridge Sites Expands into Philadelphia, Maryland, and Chicago
Cloud, Colocation, and Interconnection offered in Key Data Center Markets
June 10, 2020 06:00 AM Eastern Daylight Time
SILVER SPRING, Md.–(BUSINESS WIRE)–Three proven multi-tenant data centers have been brought together as a single-service entity by DataBridge Sites, offering cloud, colocation, and interconnection services. The three data center campuses are located in Silver Spring, Maryland, convenient to both the Washington DC and Baltimore markets; King of Prussia, Pennsylvania, serving Philadelphia; and Aurora, Illinois, a proven data center destination near Chicago.
“Due to COVID-19, companies are transitioning even more aggressively to digital operations and the ability to always be available for their customers and employees is of even greater concern than ever before”
Tweet this
DataBridge Sites is a rebranding by 20-year old ESite Systems, which in 2019 purchased Maryland and Pennsylvania data centers that had been operated by former ownership under the Agile name. All three data centers have exceptional uptime records, well-established customer bases, and offer the range of services integral to true hybrid computing.
“Our portfolio of proven data centers offers colocation and cloud services as well as direct access to multiple public cloud providers and carrier hotels,”…

National Cancer Institute (NCI) Awards Baltimore’s Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant

Published on :

University of Maryland, Baltimore (UMB) startup is part of University’s New Ventures Initiative, a highly selective program that works to accelerate commercialization and exit strategies

Rockville’s Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

Published on :

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.

Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research

Published on :

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into a licensing agreement with The Walter Reed Army Institute of Research (WRAIR) to provide APT access to the Institute’s extensive phage database. The agreement with the United States Army is synergistic with APT’s ongoing partnership with the United States Navy, providing the company with access to the pre-eminent phage database of the United States military to treat critically ill patients.